Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 16 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited announced it has obtained exclusive marketing rights for CanAssist Breast, a prognostic test for breast cancer patients. This test helps determine whether hormone positive breast cancer patients require chemotherapy, potentially avoiding unnecessary treatments. CanAssist Breast is developed by OncoStem and offers a cost-effective solution compared to existing tests performed abroad. The company aims to enhance cancer care in India by providing innovative and affordable treatment options.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases